Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | APEX1 | P27695 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9492187 | 0.81 | CRBN (0.37) | TDP1CRBN | |
| SCHEMBL5570554 | 0.77 | MAP3K14 (0.38) | MAP3K14CYP19A1MEN1APEX1KMT2A | |
| SCHEMBL13524876 | 0.74 | MAP3K14 (0.35) | MAP3K14L3MBTL1CRBN | |
| SCHEMBL22394492 | 0.74 | MAP3K14 (0.41) | MAP3K14CYP19A1MEN1APEX1KMT2A | |
| SCHEMBL6822735 | 0.71 | MAP3K14 (0.39) | MAP3K14CYP19A1MEN1APEX1KMT2A | |
| SCHEMBL11063892 | 0.70 | NPC1 (0.36) | MAP3K14CYP19A1MEN1APEX1KMT2A | |
| SCHEMBL22394491 | 0.69 | MAP3K14 (0.38) | MAP3K14CYP19A1MEN1APEX1KMT2A | |
| SCHEMBL11046047 | 0.69 | MEN1 (0.39) | MAP3K14MEN1APEX1KMT2ATDP1 | |
| SCHEMBL2956440 | 0.69 | MAP3K14 (0.44) | MAP3K14CYP19A1MEN1APEX1KMT2A | |
| SCHEMBL11122420 | 0.69 | MAP3K14 (0.44) | MAP3K14CYP19A1MEN1APEX1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113825515-A | Intracellular delivery of anti-KRAS antibodies formulated as nanocapsules | 圣地亚哥德孔波斯特拉大学 | 2021-12-21 | — | — | CN | disclosed |
| US-20090165676-A1 | BIS(N-SILYLALKYL)ASPARTIMIDES AND PROCESSES THEREFOR | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2009-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090165676-A1 | BIS(N-SILYLALKYL)ASPARTIMIDES AND PROCESSES THEREFOR | PCNA, BPHL, BYSL | MAP3K14 1054/4885CYP19A1 1912/4885MEN1 1702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.